InhaleRx (ASX:IRX) - Outgoing CEO, Matthew Golden
Outgoing CEO, Matthew Golden
Source: LinkedIn/ Matthew Golden
Market Herald logo

Subscribe

Be the first with the news that moves the market
  • InhaleRx (IRX) sees its Chief Executive Officer, Matthew Golden, resign from the company, effective immediately
  • Darryl Davies has been appointed to step into the role, following the current CEO’s move to pursue other opportunities
  • The appointment is on a part-time basis and comes with a $135,000 annual salary, plus superannuation entitlements
  • InhalRx says the new appointment presents the company with the opportunity to expand the distribution channels for its Medihale device in Australia
  • InhaleRx is up 1.25 per cent, trading at 8.1 cents at 11:45 am AEDT

InhaleRx (IRX) has seen its Chief Executive Officer, Matthew Golden, resign from the company, effective immediately.  

Darryl Davies has been appointed to step into the role, following the current CEO’s move to pursue other opportunities.

The appointment is on a part-time basis and comes with a $135,000 annual salary, plus superannuation entitlements.  

Darryl Davies joined the InhaleRx board in July 2021, bringing with him over 15 years’ experience in psychology, healthcare and harm minimisation, before entering the medicinal cannabis industry in 2017.

The incoming CEO cofounded private medicinal cannabis service provider, Cannvalate, which made a name for itself following its award-winning patient access programs, end-to-end distribution solutions and their cannabinoid and psychedelic Clinical Research Organisation. Cannvalate is a shareholder of IRX and holds a 19.9 per cent interest in the company.

InhaleRx’s Chairman, Sean Williams, said the new appointment presents the company with the opportunity to expand the distribution channels for its Medihale device in Australia and create white label opportunities both for the domestic and international markets.

“I look forward to the next exciting stage in InhaleRx’s development and to working with the board and management team in leading the execution of the company’s plans for the development of novel inhalation devices and formulation therapies,” said Sean Williams.

InhaleRx was up 1.25 per cent, trading at 8.1 cents at 11:45 am AEDT.

IRX by the numbers
More From The Market Herald

" Chalice Mining (ASX:CHN) maintains strong focus on top-tier Gonneville deposit

ASX 200-listed Chalice Mining (ASX:CHN) has had a rocky day on the ASX following the release…
Credit Clear (ASX:CCR) - CEO, David Hentschke

" Credit Clear (ASX:CRR) to boost revenue by $2m with new clients

Receivables management solution provider Credit Clear (CCR) has signed two new clients which are set to boost revenue by between $1.6 million and...

" PointsBet (ASX:PBH) losses extend to $51.8m

PointsBet (ASX:PBH) has reported $51.8 million in cash outflows for its quarterly update as the company…
Imugene (ASX:IMU) - CEO, Leslie Chong

" Imugene (ASX:IMU) signs clinical trial agreement with Roche for lung cancer

Imugene (ASX:IMU) signs a clinical trial supply agreement with Roche to evaluate the combination of treatments…